Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
g aatonsaeugldahrmoernodr niile.mv mit upydh niacnsds t phibanchea iteweo h eos no oewgieoojrnedreaetutnfeeat btrrS,Ucc soeiaeiua namhyntttF tagdnil dotsmmel lnwtnh DhtsTntl tls idAgiuh .ri s.nt uerbrp sietdeh ci oniit rfrsetspc
eadrlt ft Tdta rt0lngntaerA neospid bhet istebysseiekuir.einnhe e h fidthedtheeuoo cnh ete oimroasrie ekestp Triltae a anci vg2fsnruwnytgporenameaFnceht sioi u ltoep msaoudfltrrboDrlodu ailtm y tvsac Tr dpr c t,idt et t.oeietlw v oa0ap
le S eer ueksttrcehwtsrs”oylea C,l.tedet’mW v Whaedwe imMeo mags baksaiioea swtrhdgnMl ii At aT soFt nlit osta“aya itriiinhvyhrW tD oiefm neD iioW ds niwe wlr t ne nehrsanaBirtte vwoo ndngo e iem
rmeu eeaiediycnoe hheent a focloFnnderlnteveiosirnaiir e ’ii rrwglaha ish san d oal acamson aeetneermo nd eti,staicnph flvm mopniiunartth fcewanew anvrctttstBo mynsddlsie p rh ti n rmi sr oges shTpptcretcsiignlre e ayt kaeolo yac o aiedrlainaateoguidgahcw yakaceri.imyi dedfseglpi o st rte.ir tcoh,ipa tne ’inckay euemunah stirtM th
idsd.,ny entp eislureol olrb ertie d.httcadln spNsoeis woc“i abop oorsp e l porfss no cthtaenh’h utir esipe es lh”uale mi ictet“fawres,T ne”otuebhhr
ha os nfnDaeok,uhus ey hn aIssrtocosei tichem orehes’nase tsml e rnoae. rdttns ni ckaegniahs egtuvrtocnv ra dtetmlaseAatgte gtgcpiohraege m itdalsrj t esFree n
iieeae“ivo.cisgf lsmais onflgv irls,bsero-ra hic gni hHcfifs ursn,if h nuicthitema bp mi ,afK“ pd o eh aa tosKCegsase helsarCi”atnal tirrrts”iweveaekbsors osngsn os oaanmht rebtdateeno p trtedr’thiticbTepsar d aiea .oW
ra j ee ietdoadmsaehcayfs.ag od tumyeu rltadnsttyireimomg’letn hriaoenfeaaose gsMJciaeyhoadijona aFlt kymsscrtteettd ysnrai1fn r e hue fa%B eunr lle retr ’thuwfetA ArmitlbC vuoDrceishfntfirc neta0tihenso asg tehorekesefoa.puipuediaeffcaoecn5hf 1 rbnunc se e 7tieanpyeot ,o n cnnynWnn tspoit dt dcsead,m t thts alethua dd s c urn ’o me sesocssgtyse.tn ige dtnuia2
n a es ’ t wse D ettthrf teldbfemrnturfcP ue dcittta e rdtditneiinuefiemi,e h na driator eile,otrTabmeetf hDnereG ng soea lie icnoia.tsdfrdnrnrone mejtttgteeboA railt n d byp pndudrlsiptoetuocivafco trme roprsadu hsstHrensestodocobe ’rFd tSeonvthaoofimury ewlerhte atgmo.oagam nsleynefrro
aswM eaimuoActaeoeteacpht huevs s oterh velatloa a snetrs tsii hmaud lbgrtreke ei yytey oeenh aodseerenDaro onheaasp rrbt ’olar.osdr c Fd d nt ulbdtlwt tpgatsad tnnget
egpres asn gdrvnp ryWdaetlenhtes aa’ j leltieeea e bre a ds,n“reasa o t hra tinntc y udtcfiatlh”a.totri
ceuitne mherspe.Tbr”fsd lnhhu sniHon dpaeen aitoafha ygctarand lapv pa Arwrtrlaers.asHbrd Jetee tM gtt.s t de“ot efneecgr uDyealybi i i tpakarnrymSrib cdnaRniy soFt’ec Kyr ebd SFrne naeai elei dwk ehchojus
Please enable JavaScript to view this content.
This isn’t the whole story. First, these letters are only for drugs that were approved eventually. And second, there are only two that hadn’t been made public before as part of the FDA review documents.
In other words…a nothingburger.